Q2 2023 Earnings Forecast for Agenus Inc. (NASDAQ:AGEN) Issued By William Blair

Agenus Inc. (NASDAQ:AGEN – Get Rating) – Stock analysts at William Blair decreased their Q2 2023 earnings estimates for shares of Agenus in a research report issued to clients and investors on Tuesday, May 9th. William Blair analyst M. Phipps now anticipates that the biotechnology company will earn ($0.21) per share for the quarter, down from their previous estimate of ($0.19). The consensus estimate for Agenus’ current full-year earnings is ($0.82) per share. William Blair also issued estimates for Agenus’ Q3 2023 earnings at ($0.20) EPS, Q4 2023 earnings at ($0.21) EPS, FY2023 earnings at ($0.82) EPS, FY2024 earnings at ($0.80) EPS, FY2025 earnings at ($0.79) EPS and FY2026 earnings at ($0.42) EPS.

A number of other analysts also recently weighed in on AGEN. StockNews.com began coverage on shares of Agenus in a report on Thursday, March 16th. They issued a “sell” rating for the company. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Agenus in a research note on Tuesday, February 28th. EF Hutton Acquisition Co. I restated a “buy” rating and issued a $8.30 price objective on shares of Agenus in a research note on Tuesday, March 28th. Finally, B. Riley restated a “buy” rating and issued a $8.00 price objective on shares of Agenus in a research note on Wednesday, March 29th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.33.

Agenus Price Performance

Shares of Agenus stock opened at $1.42 on Friday. Agenus has a fifty-two week low of $1.25 and a fifty-two week high of $3.37. The firm has a fifty day moving average price of $1.57 and a two-hundred day moving average price of $2.19. The company has a market cap of $472.16 million, a PE ratio of -1.80 and a beta of 1.43.

Agenus (NASDAQ:AGEN – Get Rating) last posted its quarterly earnings data on Tuesday, March 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). Agenus had a negative return on equity of 1,159.04% and a negative net margin of 235.30%. The firm had revenue of $28.39 million for the quarter, compared to the consensus estimate of $17.83 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. U.S. Capital Wealth Advisors LLC acquired a new position in Agenus during the first quarter worth $25,000. Leisure Capital Management acquired a new position in Agenus during the third quarter worth $26,000. Commonwealth Equity Services LLC acquired a new position in Agenus during the third quarter worth $26,000. Calamos Advisors LLC acquired a new position in Agenus during the fourth quarter worth $27,000. Finally, Sei Investments Co. acquired a new position in Agenus during the first quarter worth $28,000. Institutional investors and hedge funds own 53.81% of the company’s stock.

Insider Activity

In other news, major shareholder Agenus Inc acquired 100,200 shares of Agenus stock in a transaction that occurred on Friday, May 5th. The shares were acquired at an average price of $0.95 per share, with a total value of $95,190.00. Following the purchase, the insider now directly owns 21,595,047 shares of the company’s stock, valued at $20,515,294.65. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders have acquired 250,954 shares of company stock valued at $267,492. 4.80% of the stock is currently owned by insiders.

Agenus Company Profile

(Get Rating)

Agenus, Inc is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K.